James O’Beirne

Job title

Consultant hepatologist



GMC Number


Contact details

Phone number: 020 7794 0500 ext 38097

Email address: james.o'beirne@nhs.net

PA/secretary phone number: e.croxford@nhs.net

Related services

Liver services


Dr O’Beirne trained in liver transplantation, hepatology and intensive care at the Royal Free and Kings College Hospital, London. In addtion to providing a general hepatology service he specialises in liver transplantation and provides a broad endoscopic service especially in portal hypertension. He has a particular interest in intensive care and primary liver cancer.


  • Halliday N, Smith C, Atkinson C, O'Beirne J, Patch D, Burroughs AK, Thorburn, D, Haque T. Characteristics of Epstein-Barr viraemia in adult liver transplant patients: A retrospective cohort study. Transpl Int. 2014 Apr 17.
  • Taube D, Jones G, O'Beirne J, Wennberg L, Connor A, Rasmussen A, Backman L. Generic tacrolimus in solid organ transplantation. Clin Transplant. 2014, May;28(5):623-32. 
  • Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial, chemoembolization and bland embolization for hepatocellular carcinoma. World J, Gastroenterol. 2014 Mar 28;20(12):3069-77. .
  • Lumgair HA, Rolando N, O'Beirne J, Sharma D, Griffiths PD. Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a, seronegative recipient. Transpl Infect Dis. 2014 Jun;16(3):501-4.
  • Papastergiou V, Tsochatzis EA, Pieri G, Thalassinos E, Dhar A, Bruno S, Karatapanis S, Luong TV, O'Beirne J, Patch D, Thorburn D, Burroughs AK. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther. 2014 Apr;39(7):721-32. 
  • Manousou P, Cholongitas E, Samonakis D, Tsochatzis E, Corbani A, Dhillon AP, Davidson J, Rodríguez-Perálvarez M, Patch D, O'Beirne J, Thorburn D, Luong T, Rolles K, Davidson B, McCormick PA, Hayes P, Burroughs AK. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus:randomised trial long term outcomes. Gut. 2014 Jun;63(6):1005-13.
  • Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013 Dec;59(6):1193-9. 
  • Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox, R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013 Oct;24(10):2565-70.
  • Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013 Jul;33(6):944-9. 
  • Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013 Apr 2;108(6):1252-9.
  • Manousou P, Burroughs AK, Tsochatzis E, Isgro G, Hall A, Green A, Calvaruso, V, Ma GL, Gale J, Burgess G, O'Beirne J, Patch D, Thorburn D, Leandro G, Dhillon AP. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol. 2013 May;58(5):962-8. doi:10.1016/j.jhep.2012.12.016. Epub 2012 Dec 20. 
  • Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos, E, Luong TV, Rolando N, Dhillon AP, Patch D, O'Beirne J, Thorburn D, Burroughs, AK. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013 Feb;58(2):262-70.